Pricing Log in Create free account
Saturday 17 October 2026 Export ABT’s income statement to Excel — free account

Abbott Laboratories

ABT Healthcare Medical Devices

Abbott Laboratories' revenue for fiscal 2025 (year ended December 2025) was $44.3 billion, up 5.67% from fiscal 2024. In the quarter to June 2026, revenue grew 13.0%, EPS fell 47.5%, free cash flow grew 28.9% and total debt rose 142.7%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years; insiders bought in the last twelve months.

104.88 0.20 +0.19%
Market cap
$181.1B
P/E
33.9×
Fwd P/E
22.9×
Dividend yield
2.40%
F-score
5/9
Altman Z
5.61
Beneish M
−2.50
Dividend safety
62/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Abbott Laboratories 10-K filed Feb 20, 2026

Fiscal year 2025 · Period ended Dec 31, 2025 · Filed · accepted 4:05 PM ET · Document on sec.gov · Filing index

What changed

Item 1, Business Item 1A, Risk Factors Item 7, Management’s Discussion and Analysis

Item 1, Business, against the 10-K filed Feb 21, 2025: 1 added · 24 modified; 4 with only figures updated; 1 moved without change

  1. Added · GENERAL DEVELOPMENT OF BUSINESS

    On November 19, 2025, Abbott entered into a definitive agreement to acquire Exact Sciences Corporation (Exact Sciences), which is expected to enable Abbott to enter the cancer diagnostics market. The acquisition is subject to customary closing conditions, including the approval of Exact Sciences shareholders and obtaining the required regulatory clearances.

24 more changes in this Item, word by word, in Powerpack.

Powerpack